Loading...
NPI 1992871248 · Harvey, IL · Retina Specialist (Ophthalmology) Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Zac Ravage is a retina specialist (ophthalmology) physician provider located in Harvey, Illinois. This profile covers 16 Medicare and 6 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Zac Ravage |
| Address | 71 W 156th St |
| City | Harvey |
| State | IL |
| ZIP | 60426 |
| Taxonomy | Retina Specialist (Ophthalmology) Physician |
| NPI Enumerated | November 28, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $4.2M |
| Medicaid | $167.5K |
This provider is a retina-specialist ophthalmology practice focused heavily on intravitreal anti-VEGF therapy: J0178 (aflibercept) alone accounts for $3.2M and 76.7% of the provider’s Medicare revenue, and the three highest Medicare codes together account for 88.0% of Medicare revenue. The dominant presence of J0178 plus significant volumes of injection procedure 67028 and retinal imaging 92134 indicate the operation is procedure-driven with recurring intravitreal injection visits and diagnostic imaging supporting medical retina care.
Medicare revenue ($4.2M) dwarfs Medicaid revenue ($167.5K), indicating the provider is effectively Medicare-dominant in scale; Medicaid represents a small fraction of lifetime public-payer revenue. This payer mix suggests the practice’s patient panel or reimbursement profile skews toward Medicare beneficiaries rather than Medicaid.
Revenue concentration is high on both payers: the top 3 Medicare codes drive 88.0% of total Medicare revenue while the top 3 Medicaid codes drive 97.3% of total Medicaid revenue. Both payers show a narrow service mix concentrated on intravitreal injections, associated injection procedures, and retina imaging rather than a broad set of general ophthalmology office visits.
On Medicare this provider is a national outlier for several retina-specific services: J0178 ranks #36 of 3204 providers nationally (99th percentile; described as an extreme outlier) and 92134 ranks in the 99th percentile as an extreme outlier as well, which positions the provider among the highest-volume national specialists for aflibercept administration and retinal OCT imaging. These rank positions indicate a major, high-volume role in delivering retina-focused injections and diagnostics compared with national peers.
Competitive standing on Medicaid is more muted and within typical statewide ranges: J0178 and 67028 are present in the Medicaid top codes but their in-state ranks are middling (J0178 ranks #32 of 45; 67028 ranks #49 of 120), which suggests the provider is a routine, not dominant, participant in Medicaid-funded retina services. The Medicaid code mix mirrors Medicare clinical focus but at substantially lower dollars and lower relative ranking in-state.
The procedural mix shows the practice pairs high-volume drug administration with supporting diagnostics and E/M visits: high counts for injection codes (J0178 and 67028) are complemented by substantial volumes of imaging (92134) and established-patient exams (92014, 99213). This pattern is consistent with a clinic managing chronic retinal disease requiring repeated injections and ongoing monitoring rather than episodic surgical retina or broad multispecialty ophthalmology care.
Tenure on file is long: the NPI was enumerated ~2006-11-28, indicating roughly two decades of registration. This extended active period supports the development of a high-volume, procedure-focused retinal practice and may explain consistently high Medicare volumes for specialty retina codes.
Several individual-code statistical descriptors emphasize specialty concentration rather than typical general ophthalmology volumes: 67028 is notably above typical national volume (94th percentile) and 92014 and 92134 are labeled extreme outliers or notably above typical volumes, reinforcing that the provider’s operations are highly focused on retina follow-up and imaging workflows rather than average ophthalmology practice patterns.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
16 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 4,680 | $690 | $3.2M |
| J2777 | Injection, faricimab‑svoa, 0.1 mg | 8,580 | $30 | $248.8K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 2,320 | $100 | $229.5K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 1,580 | $90 | $140.8K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 3,730 | $30 | $115.7K |
| J2778 | Injection, ranibizumab, 0.1 mg | 540 | $180 | $96.8K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 830 | $70 | $57.3K |
| 92004 | The provider performs a comprehensive level ophthalmological evaluation of a new patient and initiates a diagnostic and treatment program for one or more visits. | 250 | $120 | $28.5K |
| 92201 | The provider performs an extended ophthalmoscopy, typically with an indirect ophthalmoscope which utilizes a bright light and a hand–held indirect lens rather than the common hand–held one–piece… | 1,240 | $20 | $23.6K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 100 | $100 | $9.1K |
Showing 1–10 of 16
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 16 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
16 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J0178 | 1 | 140 | 700 | $690 | $688.4K |
| J2777 | 46 | 90 | 9,180 | $30 | $451K |
| J2778 | 12 | 20 | 540 | $180 | $214.9K |
| 67028 | 8 | 190 | 400 | $90 | $64.4K |
| 92014 | 33 | 1,420 | 130 | $80 | $24.7K |
| J9035 | 68 | 130 | 140 | $60 | $24.6K |
| 99214 | 10,126 | 18,540 | 110 | $80 | $17.1K |
| 92134 | 7 | 1,080 | 80 | $30 | $9K |
| 99213 | 318 | 17,390 | 70 | $60 | $8.8K |
| 92235 | 42 | 90 | 30 | $100 | $8.3K |
Showing 1–10 of 16
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
6 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 840 | $110 | $95.5K |
| J0178 | Injection, aflibercept, 1 mg | 80 | $620 | $49.5K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 1,500 | $10 | $18K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 130 | $30 | $3.2K |
| J9035 | Injection, bevacizumab, 10 mg | 20 | $50 | $740 |
| 92201 | The provider performs an extended ophthalmoscopy, typically with an indirect ophthalmoscope which utilizes a bright light and a hand–held indirect lens rather than the common hand–held one–piece… | 70 | $10 | $540 |
How this provider's Medicaid billing volume and revenue compare to other Illinois providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Illinois median
6 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 32 | 50 | 200 | $1,100 | $391.2K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 49 | 120 | 540 | $160 | $166.3K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 890 | 1,230 | 450 | $40 | $54.1K |
| J9035 | Injection, bevacizumab, 10 mg | 73 | 80 | 290 | $60 | $43.4K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 71 | 250 | 510 | $20 | $20.1K |
| 92201 | The provider performs an extended ophthalmoscopy, typically with an indirect ophthalmoscope which utilizes a bright light and a hand–held indirect lens rather than the common hand–held one–piece… | 29 | 50 | 110 | $10 | $5K |
Other providers in the same ZIP code as Zac Ravage, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Family Christian Health Center | IL | Federally Qualified Health Center (FQHC) | $0 | $34.1M |
| New Choice Intervention, Inc. | IL | Mental Health Clinic/Center (Including Community Mental Health Center) | $0 | $15.2M |
| Mathew Maccumber | IL | Retina Specialist (Ophthalmology) Physician | $2.7M | $1.1M |
| Sohail Hasan | IL | Retina Specialist (Ophthalmology) Physician | $3.4M | $34.2K |
| Joseph Civantos | IL | Retina Specialist (Ophthalmology) Physician | $2.7M | $537.4K |
| Vivek Chaturvedi | IL | Retina Specialist (Ophthalmology) Physician | $2.3M | $918.3K |
| Kourous Rezaei | IL | Retina Specialist (Ophthalmology) Physician | $2.7M | $0 |
| Naryan Sabherwal | IL | Retina Specialist (Ophthalmology) Physician | $1.2M | $949.6K |
| Andy Lin | IL | Clinical Cardiac Electrophysiology Physician | $660K | $451.4K |
| Michael Romberg | IL | Surgery Physician | $431.3K | $621.7K |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.